Concepedia

Author

Marjan Kuijer

National Institute for Public Health and the EnvironmentORCID

Also Known As

M. M. Kuijer, Marjan Kuijer

25

Publications

512

Citations

11

H-Index

29

Concepts

All Affiliations

National Institute for Public Health and the EnvironmentLeiden University Medical CenterErasmus MCRadboud University Medical CenterRadboud University Nijmegen
MK

About

Marjan Kuijer is an author at National Institute for Public Health and the Environment specializing in medicine, immunology, and vaccinology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

194

2

Epidemiology

3

3

64

3

Public Health

2

2

38

4

Allergy

1

1

24

5

Emergency Medicine

1

1

14

Marjan Kuijer

×

12

Publications

479

Citations

11

H-Index

YearCitations

SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence

Gerco den Hartog, Rutger M. Schepp, Marjan Kuijer,

The Journal of Infectious Diseases

2020

163

Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial

Marcia M. L. Kho, A. Lianne Messchendorp, Sophie C. Frölke,

The Lancet Infectious Diseases

2022

68

Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?

Lotus L. van den Hoogen, Gaby Smits, Cheyenne C. E. van Hagen,

Vaccine

2022

67

Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands

Lotus L. van den Hoogen, Mardi C. Boer, Abigail Postema,

Vaccines

2022

33

Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial

Margaretha Prins, Geert V.T. Roozen, Cilia R. Pothast,

npj Vaccines

2024

30

SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics

Lotus L. van den Hoogen, Marije K. Verheul, Eric R. A. Vos,

Scientific Reports

2022

24

Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study

Geert V.T. Roozen, Margaretha Prins, Rob van Binnendijk,

Annals of Internal Medicine

2022

24

SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence

Gerco den Hartog, Rutger M. Schepp, Marjan Kuijer,

2020

17

Infant antibody levels following 10-valent pneumococcal-protein D conjugate and DTaP-Hib vaccinations in the first year of life after maternal Tdap vaccination: An open-label, parallel, randomised controlled trial

Daan Barug, Guy A. M. Berbers, Marlies A. van Houten,

Vaccine

2020

14

Tolerability, Safety and Immunogenicity of Intradermal Delivery of a Fractional Dose mRNA -1273 SARS-CoV-2 Vaccine in Healthy Adults as a Dose Sparing Strategy

Geert V.T. Roozen, Margaretha Prins, Robert Samuel van Binnendijk,

SSRN Electronic Journal

2021

14

Page 1